Indaptus Therapeutics (INDP)

• Market cap: $4.32M
• 1 day: 5.41%
• 5 days: -2.74%
• 1 month: 37.32%
• 3 months: -64.22%
• 6 months: -70.05%
• Year to date: -83.7%
• 1 year: -90.52%
• 5 years: -99.26%
• 10 years: -99.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Employees: 7